OncoMatch/Clinical Trials/NCT04813705
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
Is NCT04813705 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Chemotherapy for nasopharyngeal carcinoma.
Treatment: Chemotherapy — The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage I, II, III, IVA
Demographics
Prior therapy
Cannot have received: radiation therapy
Exception: non-melanomatous skin cancers outside intended RT treatment volume
History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).
Cannot have received: chemotherapy
Prior chemotherapy ... to primary tumor or nodes.
Cannot have received: surgery
Exception: diagnostic
Prior ... surgery (except diagnostic) to primary tumor or nodes.
Lab requirements
Blood counts
HGB≥90 g/L, ANC≥1.5×10^9/L, PLT≥80×10^9/L.
Kidney function
CCR≥60ml/min or Cr<1.5×ULN.
Liver function
ALT, AST <2.5 fold of ULN; TBIL <2.0×ULN.
HGB≥90 g/L，ANC≥1.5×10^9 /L，PLT≥80×10^9 /L. ALT,AST<2.5 fold of ULN；TBIL<2.0×ULN. CCR≥60ml/min or Cr<1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04813705 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I or II or III or IVA is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages